Summary

Human Papilloma Virus Testing Market Summary

The human papilloma virus testing market size was estimated at USD 1.76 billion in 2024 and is projected to reach USD 5.67 billion by 2033, growing at a CAGR of 14.14% from 2025 to 2033. The market is fueled by rising HPV-related cancer cases, with human papilloma virus (HPV) causing over 95% of cervical cancers.


Countries like Australia have replaced Pap smears with HPV DNA testing for higher sensitivity. Self-sampling kits, such as those from BD and Hologic, are expanding access in underserved areas. WHO’s elimination strategy and NGO-backed programs in Africa and Asia drive adoption. Advances in molecular diagnostics, bundled women’s health panels, and improved lab infrastructure make testing more accessible and cost-effective globally. Cervical cancer is the fourth most common cancer among women worldwide and the second leading cause of female cancer-related mortality.

In November 2020, the World Health Organization launched its Global Strategy to Eliminate Cervical Cancer, setting the 90-70-90 targets for 2030-vaccinate 90% of girls by age 15, screen 70% of women at ages 35 and 45, and treat 90% of women with identified disease. This initiative came against alarming statistics: in 2022, only 18% of countries had reached the recommended screening coverage of over 70%, and global coverage still stood at about 20%. HPV is the causative agent in 99.8% of cervical cancer cases, with genotypes 16 and 18 alone responsible for 70% of cases. Nineteen high-risk genotypes account for 90% of all HPV-related cancers. Given the asymptomatic nature of most HPV infections, molecular testing has become essential for early detection. Since 2017, countries such as Australia and the Netherlands have transitioned from Pap smears to primary HPV DNA testing, citing higher sensitivity and longer screening intervals.

Global Human Papilloma Virus Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global human papilloma virus (HPV) testing market report based on application, product, technology, end use, and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cervical Cancer Screening
• Vaginal Cancer Screening
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Consumables
• Services
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• PCR
• Immunodiagnostics
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Application
1.2.2. Product
1.2.3. Technology
1.2.4. End Use
1.2.5. Regional Scope
1.2.6. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application Outlook
2.2.2. Product Outlook
2.2.3. Technology Outlook
2.2.4. End Use Outlook
2.2.5. Regional Outlook
2.3. Competitive Scenario
Chapter 3. Human Papilloma Virus (HPV) Testing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Human Papilloma Virus (HPV) Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. Human Papilloma Virus (HPV) Testing Market: Application Estimates & Trend Analysis
4.1. Application Segment Dashboard
4.2. Human Papilloma Virus (HPV) Testing Market: Application Movement Analysis
4.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Application, 2021 - 2033 (USD Million)
4.4. Cervical Cancer Screening
4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Vaginal Cancer Screening
4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Human Papilloma Virus (HPV) Testing Market: Product Estimates & Trend Analysis
5.1. Product Segment Dashboard
5.2. Human Papilloma Virus (HPV) Testing Market: Product Movement Analysis
5.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Product, 2021 - 2033 (USD Million)
5.4. Instruments
5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Consumables
5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Services
5.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Human Papilloma Virus (HPV) Testing Market: Technology Estimates & Trend Analysis
6.1. Technology Segment Dashboard
6.2. Human Papilloma Virus (HPV) Testing Market: Technology Movement Analysis
6.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Technology, 2021 - 2033 (USD Million)
6.4. PCR
6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Immunodiagnostics
6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Others
6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Human Papilloma Virus (HPV) Testing Market: End Use Estimates & Trend Analysis
7.1. End Use Segment Dashboard
7.2. Human Papilloma Virus (HPV) Testing Market: End Use Movement Analysis
7.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By End Use, 2021 - 2033 (USD Million)
7.4. Hospitals & Clinics
7.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Laboratories
7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Human Papilloma Virus (HPV) Testing Market: Regional Estimates & Trend Analysis
8.1. Regional Market Dashboard
8.2. Regional Market Share Analysis, 2021 & 2033
8.3. Human Papilloma Virus (HPV) Testing Market by Region: Key Takeaways
8.4. North America
8.4.1. U.S.
8.4.1.1. Key Country Dynamics
8.4.1.2. Regulatory Framework/ Reimbursement Structure
8.4.1.3. Competitive Scenario
8.4.1.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.2. Canada
8.4.2.1. Key Country Dynamics
8.4.2.2. Regulatory Framework/ Reimbursement Structure
8.4.2.3. Competitive Scenario
8.4.2.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.3. Mexico
8.4.3.1. Key Country Dynamics
8.4.3.2. Regulatory Framework/ Reimbursement Structure
8.4.3.3. Competitive Scenario
8.4.3.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Europe
8.5.1. Germany
8.5.1.1. Key Country Dynamics
8.5.1.2. Regulatory Framework/ Reimbursement Structure
8.5.1.3. Competitive Scenario
8.5.1.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Regulatory Framework/ Reimbursement Structure
8.5.2.3. Competitive Scenario
8.5.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.3. France
8.5.3.1. Key Country Dynamics
8.5.3.2. Regulatory Framework/ Reimbursement Structure
8.5.3.3. Competitive Scenario
8.5.3.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.4. Italy
8.5.4.1. Key Country Dynamics
8.5.4.2. Regulatory Framework/ Reimbursement Structure
8.5.4.3. Competitive Scenario
8.5.4.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.5. Spain
8.5.5.1. Key Country Dynamics
8.5.5.2. Regulatory Framework/ Reimbursement Structure
8.5.5.3. Competitive Scenario
8.5.5.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.6. Denmark
8.5.6.1. Key Country Dynamics
8.5.6.2. Regulatory Framework/ Reimbursement Structure
8.5.6.3. Competitive Scenario
8.5.6.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.7. Sweden
8.5.7.1. Key Country Dynamics
8.5.7.2. Regulatory Framework/ Reimbursement Structure
8.5.7.3. Competitive Scenario
8.5.7.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.8. Norway
8.5.8.1. Key Country Dynamics
8.5.8.2. Regulatory Framework/ Reimbursement Structure
8.5.8.3. Competitive Scenario
8.5.8.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Japan
8.6.1.1. Key Country Dynamics
8.6.1.2. Regulatory Framework/ Reimbursement Structure
8.6.1.3. Competitive Scenario
8.6.1.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.2. China
8.6.2.1. Key Country Dynamics
8.6.2.2. Regulatory Framework/ Reimbursement Structure
8.6.2.3. Competitive Scenario
8.6.2.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.3. India
8.6.3.1. Key Country Dynamics
8.6.3.2. Regulatory Framework/ Reimbursement Structure
8.6.3.3. Competitive Scenario
8.6.3.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.4. South Korea
8.6.4.1. Key Country Dynamics
8.6.4.2. Regulatory Framework/ Reimbursement Structure
8.6.4.3. Competitive Scenario
8.6.4.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. Regulatory Framework/ Reimbursement Structure
8.6.5.3. Competitive Scenario
8.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.6. Thailand
8.6.6.1. Key Country Dynamics
8.6.6.2. Regulatory Framework/ Reimbursement Structure
8.6.6.3. Competitive Scenario
8.6.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory Framework/ Reimbursement Structure
8.7.2.3. Competitive Scenario
8.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory Framework/ Reimbursement Structure
8.7.3.3. Competitive Scenario
8.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East and Africa
8.8.1. Middle East and Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Regulatory Framework/ Reimbursement Structure
8.8.2.3. Competitive Scenario
8.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Regulatory Framework/ Reimbursement Structure
8.8.3.3. Competitive Scenario
8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Regulatory Framework/ Reimbursement Structure
8.8.4.3. Competitive Scenario
8.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Regulatory Framework/ Reimbursement Structure
8.8.5.3. Competitive Scenario
8.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/ Competition Categorization
9.3. Vendor Landscape
9.3.1. Key Company Heat Map Analysis, 2024
9.4. Company Profiles
9.4.1. Abbott
9.4.1.1. Company Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Biomedical Diagnostics
9.4.2.1. Company Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. bioMerieux
9.4.3.1. Company Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Bio-Rad Laboratories, Inc.
9.4.4.1. Company Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Fujirebio
9.4.5.1. Company Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Oncolab
9.4.6.1. Company Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Hologic, Inc.
9.4.7.1. Company Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. Qiagen
9.4.8.1. Company Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. F. Hoffmann-La Roche Ltd
9.4.9.1. Company Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. Siemens Healthineers AG
9.4.10.1. Company Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives